Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, ...

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi ...

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive ...

TUESDAY, August 5, 2025 (HealthDay News) — C. diff, which is short for Clostridioides difficile, is a type of bacteria that ...

When bacterial pathogens enter our bodies, they've got one goal-hunt for food to multiply. And during the process, they make us sick. Inside the Skaar ...

The Trump administration is decreasing funding for the development of mRNA (messenger RNA) vaccines, which were crucial in ...

Probiotics were favored over placebo for CDI prevention, particularly with twice-daily dosing, but their overall effect on disease incidence was not significant.

RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.

As a kid, I remember having a rash after taking penicillin. To this day, my doctor prescribes something other than penicillin ...